Literature DB >> 29063720

Association of CDKN2A/CDKN2B with inflammatory bowel disease in Koreans.

Ho-Su Lee1, Soo Bin Lee1, Byoung Mok Kim1, Myunghee Hong1, Seulgi Jung1, Jeonghoon Hong1, Jiwon Baek1, Buhm Han2, Seak Hee Oh3, Kyung Mo Kim3, Sang Hyoung Park4, Suk-Kyun Yang4, Byong Duk Ye4, Kyuyoung Song1.   

Abstract

BACKGROUND AND AIM: CDKN2A/CDKN2B locus on 9p21 is reported to be associated with various diseases, including cancer and cardiovascular and inflammatory diseases. Significant downregulation of CDKN2B-AS1 in inflamed colon tissue of inflammatory bowel disease (IBD) cases was reported in Europeans. This study aimed to confirm the suggestive association of CDKN2A/CDKN2B with IBD identified in our recent genome-wide association study (GWAS).
METHODS: We examined the association of CDKN2A/CDKN2B locus with IBD in an additional sample of 574 IBD cases and 542 controls, totaling 4068 cases and 8074 controls. In silico study was performed at various levels for functional annotation of the causal variant. Co-localization of the GWAS association signals and the corresponding expression quantitative trait loci in IBD-related tissues was evaluated using eCAVIAR.
RESULTS: An expanded GWAS showed genome-wide significant association of rs3731257 at 9p21 with IBD (odds ratio = 1.17, 95% confidence interval = 1.12-1.22, Pcombined  = 5.68 × 10-9 ) and Crohn's disease (odds ratio = 1.22, 95% confidence interval = 1.15-1.28, Pcombined  = 8.85 × 10-9 ) in the Korean population. Co-localization study suggested that both CDKN2B-AS1 and CDKN2A might be functionally associated with the locus in the small intestine.
CONCLUSIONS: rs3731257 in CDKN2A/CDKN2B is an IBD-susceptible locus in Koreans, with a suggestive role for small intestine-specific gene regulation. Our findings suggested that alterations of the CDKN2A/CDKN2B locus could affect the pathophysiology of IBD.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  CDKN2A/CDKN2B; Korea; genetics; inflammatory bowel disease; risk loci

Mesh:

Substances:

Year:  2018        PMID: 29063720     DOI: 10.1111/jgh.14031

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

1.  LncRNA CDKN2B-AS1 Promotes Cell Viability, Migration, and Invasion of Hepatocellular Carcinoma via Sponging miR-424-5p.

Authors:  Xinying Shen; Yong Li; Fan He; Jian Kong
Journal:  Cancer Manag Res       Date:  2020-08-04       Impact factor: 3.989

2.  Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression.

Authors:  Haocheng Li; Song Han; Qingfeng Sun; Ye Yao; Shiyong Li; Chao Yuan; Bo Zhang; Bao Jing; Jia Wu; Ye Song; Haiyang Wang
Journal:  Aging (Albany NY)       Date:  2019-03-29       Impact factor: 5.682

3.  Expression Quantitative Trait Loci (eQTL) Mapping in Korean Patients With Crohn's Disease and Identification of Potential Causal Genes Through Integration With Disease Associations.

Authors:  Seulgi Jung; Wenting Liu; Jiwon Baek; Jung Won Moon; Byong Duk Ye; Ho-Su Lee; Sang Hyoung Park; Suk-Kyun Yang; Buhm Han; Jianjun Liu; Kyuyoung Song
Journal:  Front Genet       Date:  2020-05-14       Impact factor: 4.599

4.  Splenic Transcriptional Responses in Severe Visceral Leishmaniasis: Impaired Leukocyte Chemotaxis and Cell Cycle Arrest.

Authors:  Caroline Vilas Boas de Melo; Felipe Guimarães Torres; Micely D'El-Rei Hermida; Jonathan L M Fontes; Bianca Ramos Mesquita; Reginaldo Brito; Pablo Ivan P Ramos; Gabriel R Fernandes; Luiz Antônio Rodrigues Freitas; Ricardo Khouri; Carlos Henrique Nery Costa; Washington L C Dos-Santos
Journal:  Front Immunol       Date:  2021-11-05       Impact factor: 7.561

5.  Host Genetic and Gut Microbial Signatures in Familial Inflammatory Bowel Disease.

Authors:  Yoo Min Park; Eunji Ha; Ki-Nam Gu; Ga Young Shin; Chang Kyun Lee; Kwangwoo Kim; Hyo Jong Kim
Journal:  Clin Transl Gastroenterol       Date:  2020-07       Impact factor: 4.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.